Skip to content

Efficacy and safety evaluation study of add-on therapy of hyaluronic acid complex to anticholinergics in overactive bladder male patients

Efficacy and safety of add-on therapy of hyaluronic acid complex to anticholinergics in overactive bladder male patients: a prospective, randomized, placebo-controlled, comparative clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0004168
Enrollment
50
Registered
2019-08-08
Start date
2019-10-07
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Efficacy and safety of add-on therapy of hyaluronic acid complex to anticholinergics in overactive bladder male patients: a prospective, placebo-controlled, 1:1 randomized, compa

Sponsors

Koera University Guro Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: ? Male patient who visited urology department with overactive bladder according to ICS criteria or male patients who visited urology department due to lower urinary tract symptoms and patients with overactive bladder according to ICS criteria despite of a-blocker treatment ? Patients with an OABSS total score = 3 and No. 3 (urgent urine) = 2 score ? Those who have voluntarily agreed in writing to participate in this study

Exclusion criteria

Exclusion criteria: ? Patient whose bacterium is cultured by urinalysis ? Patients with urethral or bladder neck stenosis ? Patients with urinary stones ? cancer in urinary tract ? Patients with urethral diverticulum ? Patients with Tuberculosis ? Patients with a history of pelvic radiation therapy ? Those who can not follow up until 3 months after treatment

Design outcomes

Primary

MeasureTime frame
Mean OABSS score before and after treatment in both groups

Secondary

MeasureTime frame
Difference between the two groups in terms of mean IPSS scores;Difference between the two groups in terms of mean IPSS subscores(storage symptoms, voiding symptoms, and QOL(quality of life));Difference between the two groups in terms of mean OABSS subscores (Urgency, Daytime Frequency, Night-Time Frequency, and Urgency Incontinence);safety evaluation: side effects, laboratory test results

Countries

Korea, Republic of

Contacts

Public ContactDugeon Moon

Koera University Guro Hospital

uromoon@gmail.com+82-2-1577-9966

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026